Cytek Biosciences (CTKB) Enterprise Value (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Enterprise Value data on file, last reported at -$65.7 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 31.06% year-over-year to -$65.7 million; the trailing twelve-month figure through Mar 2026 stood at -$65.7 million (up 31.06% YoY), and the FY2025 full-year result was -$90.9 million, up 7.99% from the prior year.
• Enterprise Value for Q1 2026 stood at -$65.7 million, up from -$90.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$65.7 million in Q1 2026 and bottomed at -$349.9 million in Q2 2022.
• The 5-year median for Enterprise Value is -$162.3 million (2024), against an average of -$174.1 million.
• The widest annual swing landed in 2022, when Enterprise Value slumped 118.9%; it then surged 62.41% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$299.5 million in 2022, then surged by 44.03% to -$167.6 million in 2023, then jumped by 41.09% to -$98.7 million in 2024, then advanced by 7.99% to -$90.9 million in 2025, then gained by 27.69% to -$65.7 million in 2026.
• The last three Enterprise Value figures came in at -$65.7 million (Q1 2026), -$90.9 million (Q4 2025), and -$93.3 million (Q3 2025), per Business Quant data.

Peer Comparison